Chinese biotech developing semaglutide biosimilar files for Hong Kong IPO
A Chinese company with plans to commercialize biosimilar GLP-1 drugs is seeking to go public in Hong Kong, in a test of investor enthusiasm amid …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
